These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38561040)

  • 21. Audio Interview: A Potential New Agent to Treat Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(26):e101. PubMed ID: 34936745
    [No Abstract]   [Full Text] [Related]  

  • 22. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
    Dabbous HM; El-Sayed MH; El Assal G; Elghazaly H; Ebeid FFS; Sherief AF; Elgaafary M; Fawzy E; Hassany SM; Riad AR; TagelDin MA
    Sci Rep; 2021 Mar; 11(1):7282. PubMed ID: 33790308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Cheema HA; Ali A; Ali M; Shahid A; Ghafoor MS; Ur Rehman ME; Sah R; Sahra S; Ahmad S
    Am J Ther; 2024 May-Jun 01; 31(3):e328-e331. PubMed ID: 37647511
    [No Abstract]   [Full Text] [Related]  

  • 26. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
    Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
    Ömeroğlu ŞK; Temel F; Altun D; Öztop B
    Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations.
    Saraya RE; Deeb SE; Salman BI; Ibrahim AE
    J Sep Sci; 2022 Jul; 45(14):2582-2590. PubMed ID: 35583051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
    Manabe T; Kambayashi D; Akatsu H; Kudo K
    BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
    Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
    Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molnupiravir: A new candidate for COVID-19 treatment.
    Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.
    Standing JF; Buggiotti L; Guerra-Assuncao JA; Woodall M; Ellis S; Agyeman AA; Miller C; Okechukwu M; Kirkpatrick E; Jacobs AI; Williams CA; Roy S; Martin-Bernal LM; Williams R; Smith CM; Sanderson T; Ashford FB; Emmanuel B; Afzal ZM; Shields A; Richter AG; Dorward J; Gbinigie O; Van Hecke O; Lown M; Francis N; Jani B; Richards DB; Rahman NM; Yu LM; Thomas NPB; Hart ND; Evans P; Andersson M; Hayward G; Hood K; Nguyen-Van-Tam JS; Little P; Hobbs FDR; Khoo S; Butler C; Lowe DM; Breuer J;
    Nat Commun; 2024 Feb; 15(1):1652. PubMed ID: 38396069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Favipiravir for treating COVID-19.
    Korula P; Alexander H; John JS; Kirubakaran R; Singh B; Tharyan P; Rupali P
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD015219. PubMed ID: 38314855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Immun Inflamm Dis; 2024 Apr; 12(4):e1262. PubMed ID: 38652021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis.
    Zheng Z; Zhou J; Song Y
    Iran J Med Sci; 2024 May; 49(5):275-285. PubMed ID: 38751873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis.
    Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M
    APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.